NS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey

Basit Öğe Kaydı
dc.authoridSAYAN, MURAT/0000-0002-4374-7193
dc.authoridALTINTAS, ENGIN/0000-0003-0796-1456
dc.authoridALTUNCEKIC YILDIRIM, ARZU/0000-0003-1141-9838
dc.authoridSirin, Goktug/0000-0002-6945-3193
dc.contributor.authorSayan, Murat
dc.contributor.authorYildirim, Figen Sarigul
dc.contributor.authorAkhan, Sila
dc.contributor.authorYildirim, Arzu Altuncekic
dc.contributor.authorSirin, Goktug
dc.contributor.authorCabalak, Mehmet
dc.contributor.authorDemir, Mehmet
dc.date.accessioned2025-01-27T21:04:18Z
dc.date.available2025-01-27T21:04:18Z
dc.date.issued2020
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjectives: Chronic hepatitis C (CHC) is now a more curable disease with new direct acting antivirals (DAA). Although high sustained virologic response rates, failures still occur in DAA regimens. Our objective in this study was to characterize the real-life presence of clinically relevant resistance - associated substitutions (RASs) in the HCV NS5A gene in CHC patients whose DAA regimen has failed. Methods: The study enrolled 53 CHC patients who experienced failure with DAA regimen as the prospective longitudinal cohort between 2017-2019. Genotypic resistance testing was performed via the viral population sequencing method and The Geno2pheno HCV tool was used for RAS analysis. Results: The most frequent failure category was relapse (88%) followed by non-responder (12%). For a total of 36% of patients, RASs was detected in NS5A, Y93H was the most detected RAS in GT1b infected patients (89%). Conclusions: This study establishes an HCV failure registry for Turkey in which samples were combined with clinical, virologic and molecular data of adult patients whose DAA therapy failed. RASs can occur in CHC patients with DAA treatment failures. Evaluation of RAS after DAA failure is very important before retreatment is initiated to prevent virologic failure. (C) 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
dc.identifier.doi10.1016/j.ijid.2020.03.061
dc.identifier.endpage89
dc.identifier.issn1201-9712
dc.identifier.issn1878-3511
dc.identifier.pmid32302766
dc.identifier.scopus2-s2.0-85083589273
dc.identifier.scopusqualityQ1
dc.identifier.startpage84
dc.identifier.urihttps://doi.org/10.1016/j.ijid.2020.03.061
dc.identifier.urihttps://hdl.handle.net/20.500.12428/27608
dc.identifier.volume95
dc.identifier.wosWOS:000540737100014
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Sci Ltd
dc.relation.ispartofInternational Journal of Infectious Diseases
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectHepatitis C
dc.subjectHepatitis C virus
dc.subjectNS-5 protein
dc.subjectTreatment failure
dc.subjectSequence analysis
dc.titleNS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu